CBI

Leading life science success

CBI is Israel’s largest life sciences holding company

about cbi

Clal Biotechnology Industries (TASE: CBI) is Israel’s leading life sciences investment company. CBI supports life sciences by identifying and powering science backed ventures and proactively guiding them to transform the healthcare industry.

portfolio

The CBI portfolio is comprised of biotechnology and medical device companies developing breakthrough solutions for serious unmet medical needs, while offering substantial value and investment potential.

+

MediWound

MediWound (Nasdaq: MDWD) is a specialty biotechnology company focused on the fields of severe burn and chronic wound management.
+

Gamida Cell

Gamida Cell is a cell and immune therapy visionary. Lead product, NiCord® is currently in phase III clinical trial in hematological malignancies.
+

Anchiano (formerly Biocancell)

Anchiano (TASE: ANCN) is a clinical stage biopharmaceutical company dedicated to developing new therapies for non-muscle-invasive bladder cancer.
+

Vedantra

Vedantra develops platform technologies to deliver agents directly to the antigen-presenting cells of the lymph nodes with potential application in both cancer and infectious disease.
+

Neon Therapeutics

Neon Therapeutics is a clinical stage, immuno-oncology company focused on developing novel therapeutics leveraging neoantigen biology to treat cancer.
+

Cadent Therapeutics

Cadent Therapeutics is a precision medicine company developing novel drugs for neurological and psychiatric disorders.
+

Exithera

eXIthera Pharmaceuticals is a clinical stage biotech company focused on discovering and developing Factor XIa inhibitors for the prevention of stroke and thrombosis.
+

Biokine

Biokine Therapeutics is company focused on developing novel therapeutics to treat cancer. It's lead product, BL-8040, is licensed to BiolineRx and is entering phase III clinical trial.
+

CureTech

CureTech is a biotechnology company developing novel immune modulating products. Its lead product, pidilizumab (CT-011), was evaluated in multiple cancer indications.

See complete portfolio

Press Releases

2018

12

Dec

Pi-Cardia Completes $3 Million Financing
12

Dec

BioLineRx Announces Initiation of BL-8040, Keytruda and Chemotherapy Combination Arm in the Phase 2a COMBAT/KEYNOTE-202 Pancreatic Cancer Trial
09

Dec

First Patient Dosed in Neon Therapeutics’ Phase 1b NT-003 Combination Trial of NEO-PV-01 in Metastatic Melanoma
03

Dec

Gamida Cell Presents Immune Reconstitution Data from NiCord® Completed Phase 1/2 Trial at ASH 2018 Annual Meeting
27

Nov

Gamida Cell – Increase in IPO proceeds to $53 million as underwriters exercise purchase option of additional shares
18

Nov

Cadent Therapeutics Starts Phase I Trial with Essential Tremor Drug Candidate, Secures $40 Million to Advance Pipeline for Movement and Cognitive Disorders

Read all Press Releases